文献速递肺外科心外重症与机械循环支持

肺移植术后原发性移植物功能障碍需体外膜氧合支持的结局

Outcomes of Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction After Lung Transplantation.
PubMed 文献 · Ann Thorac Surg · 2023-01-10

该单中心回顾性队列研究纳入773例肺移植受者,其中204例(26%)在术后72小时内发生3级原发性移植物功能障碍,13例(5%)需VA ECMO、25例(10%)需VV ECMO支持。VA ECMO组30天、1年、5年生存率分别为62%、54%、43%,低于VV ECMO组的96%、84%、65%和非ECMO组的99%、94%、71%;多变量Cox回归显示VA ECMO与死亡率升高相关(HR 2.37,95%CI 1.06-5.28,P=0.04)。

要点

  • 3级原发性移植物功能障碍需VA ECMO者30天生存率62%,低于VV ECMO组的96%和非ECMO组的99%。
  • VA ECMO与死亡率升高独立相关(HR 2.37,95%CI 1.06-5.28,P=0.04)。
  • 作者认为VA ECMO治疗肺移植术后3级原发性移植物功能障碍可能是可预测的死亡风险因素。

核心结论

  • 因3级原发性移植物功能障碍需VA ECMO支持的患者生存率显著低于无需ECMO及需VV ECMO支持者。
  • 作者认为VA ECMO治疗肺移植术后3级原发性移植物功能障碍可能是可预测的死亡风险因素。

研究设计与样本

  • 单中心回顾性队列研究,纳入773例肺移植受者。
  • 将术后发生3级原发性移植物功能障碍的患者分为非ECMO组、VA ECMO组和VV ECMO组,比较组间结局。

主要发现

  • 773例肺移植受者中,204例(26%)在术后72小时内发生3级原发性移植物功能障碍。
  • 204例中,13例(5%)需VA ECMO支持,25例(10%)需VV ECMO支持。
  • VA ECMO组30天、1年、5年生存率分别为62%、54%、43%,VV ECMO组分别为96%、84%、65%,非ECMO组分别为99%、94%、71%。
  • 多变量Cox回归分析显示,VA ECMO与死亡率升高相关(HR 2.37,95%CI 1.06-5.28,P=0.04)。

临床怎么用

  • 作者认为VA ECMO治疗肺移植术后3级原发性移植物功能障碍可能是可预测的死亡风险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary graft dysfunction (PGD) is the leading cause of death in the first 30 days after lung transplantation and is also associated with worse long-term outcomes. Outcomes of patients with PGD grade 3 requiring extracorporeal membrane oxygenation (ECMO) support after lung transplantation have yet to be well described. We sought to describe short- and long-term outcomes for patients with PGD grade 3 who required ECMO support. METHODS: This is a single-center retrospective cohort study of patients undergoing lung transplantation. We stratified patients with PGD grade 3 into non-ECMO, venoarterial (VA) ECMO, and venovenous (VV) ECMO groups after transplantation. We then compared the outcomes between the groups. RESULTS: Of 773 lung transplant recipients, PGD grade 3 developed in 204 (26%) at any time in the first 72 hours after lung transplantation. Of these, 13 (5%) required VA ECMO and 25 (10%) required VV ECMO support. The 30-day, 1-year, and 5-year survival in the VA ECMO group was 62%, 54%, and 43% compared with 96%, 84%, and 65% in the VV ECMO group and 99%, 94%, and 71% in the non-ECMO group. Multivariable Cox regression analysis showed that VA ECMO was associated with increased mortality (hazard ratio, 2.37; 95% CI, 1.06-5.28; P = .04). CONCLUSIONS: Patients who required VA ECMO support for PGD grade 3 have significantly worse survival compared with those who did not require ECMO and those who required VV ECMO support. This suggests that VA ECMO treatment of patients with PGD grade 3 after lung transplantation can be a predictable risk factor for mortality.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Takahashi T, Terada Y, Pasque MK, et al. Outcomes of Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction After Lung Transplantation. Ann Thorac Surg. 2023. PMID: 36634836. doi:10.1016/j.athoracsur.2022.12.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。